Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25222741 | 0.88 | JAK2 (0.34) | LPLLIPGJAK2BTK | |
| SCHEMBL16815439 | 0.86 | LPL (0.40) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL25668459 | 0.85 | — | — | |
| SCHEMBL26927372 | 0.84 | JAK2 (0.34) | LPLLIPGJAK2BTK | |
| SCHEMBL23409514 | 0.81 | LPL (0.37) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL8236344 | 0.80 | LPL (0.36) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL1646761 | 0.80 | LPL (0.44) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL25503944 | 0.79 | LPL (0.42) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL22190744 | 0.79 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL24348507 | 0.78 | LPL (0.37) | LPLLIPGJAK2BTKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11661412-B2 | Organic molecules for use in organic optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | LPL 704/4885LIPG 455/4885JAK2 3658/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | LPL 704/4885LIPG 455/4885JAK2 3658/4885 |
| US-11661412-B2 | Organic molecules for use in organic optoelectronic devices | OR10J3, OR51E2, AOX1 | LPL 4468/4885LIPG 2201/4885JAK2 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.